Rationale and design of a randomized trial of automated hovering for post–myocardial infarction patients: The HeartStrong program
Andrea B. Troxel(Andover Eye Associates), Kevin G. Volpp(Philadelphia VA Medical Center), Shivan J. Mehta(Philadelphia VA Medical Center), Tirza Areli Calderón(University of Pennsylvania), R. K. S. Lim(University of Pennsylvania Health System), David A. Asch(University of Pennsylvania), Brian Drachman(Penn Presbyterian Medical Center), Daniel M. Kolansky(Hospital of the University of Pennsylvania), Devon Taylor(University of Pennsylvania), Jingsan Zhu(University of Pennsylvania), Laurie Norton(University of Pennsylvania)
Cited by 13
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
|New England Journal of Medicine|2020|1.1k
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis
|Circulation Heart Failure|2019|560
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
|Journal of the American College of Cardiology|2016|540